Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 2

Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

Panelists discuss how recent trials evaluating quadruplet regimens in transplant-ineligible/deferred NDMM, including IMROZ and BENEFIT, demonstrate promising efficacy with isatuximab-VRd combinations showing comparable MRD negativity rates to CEPHEUS’ daratumumab-VRd data, though cross-trial comparisons require careful interpretation.

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
Now Viewing
EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

Video content above is prompted by the following:

  • Please comment on other quadruplet regimens in the TIE or deferred NDMM space.
  • Briefly discuss IMROZ(isatuximab [Isa]-VRd vs VRd)
  • IMROZ, MRD negativity
  • Briefly discuss BENEFIT (Isa-VRd vs Isa-Rd)
  • Thinking back to CEPHEUS, how do data from these trials compare?